tert-butyl-(2-chloro-phenyl)-amine | 939-36-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: tert-butyl-(2-chloro-phenyl)-amine
• 英文别名: N-tert-Butyl-2-chloroaniline；o-Chlor-N-tert.-butyl-anilin；o-Chloro-N-tert.-butylanilin；N-tert.Butyl-o-chloranilin；o-Chlor-N-t-butylanilin；Aniline, N-tert-butyl-2-chloro-
• CAS: 939-36-6
• 化学式: C₁₀H₁₄ClN
• mdl: MFCD22083155
• 分子量: 183.681
• InChiKey: MPDOKHFNDKPACR-UHFFFAOYSA-N

物化性质

• 沸点：
  258.4±13.0 °C(Predicted)
• 密度：
  1.077±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  tert-butyl-(2-chloro-phenyl)-amine 在 N,N-二甲基苯胺 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 1.5h， 生成 Dithiocarbonic acid S-{[tert-butyl-(2-chloro-phenyl)-carbamoyl]-methyl} ester O-ethyl ester
  参考文献：
  名称：

  An Unusual Radical Smiles Rearrangement

  摘要：

  Radicals derived from N-(alpha-xanthyl)acetanilides or N-(alpha-xanthyl)acetylaminopyridines possessing a substituent next to the nitrogen undergo a hitherto undocumented Smiles rearrangement proceeding through a four-membered ring. It was also found that under certain conditions the amidyl radical produced by cleavage of the four-membered ring intermediate can undergo fragmentation to give an isocyanate. Such fragmentations are unprecedented at temperatures corresponding to refluxing benzene or chlorobenzene.

  DOI：

  10.1021/ol051568l
• 作为产物：
  描述：

  邻氯苯胺 以78%的产率得到
  参考文献：
  名称：

  Gage James R., Wagner Jill M., J. Org. Chem., 60 (1995) N 8, S 2613-2614

  摘要：

  DOI：

文献信息

• POTASSIUM CHANNEL MODULATORS
  申请人：Cadent Therapeutics, Inc.

  公开号：US20170355708A1

  公开（公告）日：2017-12-14

  Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.

  提供的是公式(I)的新颖化合物： 以及它们的药用可接受盐，这些化合物用于治疗与钾通道相关的一系列疾病、障碍或状况。还提供了包含公式(I)的新颖化合物的药物组合物，它们的药用可接受盐，以及使用它们来治疗与钾通道相关的一种或多种疾病、障碍或状况的方法。
• [EN] CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS<br/>[FR] QUINOLINES CONDENSÉES UTILISÉES COMME MODULATEURS DES PROTÉINES KINASES
  申请人：CYLENE PHARMACEUTICALS INC

  公开号：WO2011025859A1

  公开（公告）日：2011-03-03

  The invention relates in part to molecules of formula (I) having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate protein kinase CK2 activity, Pim kinase activity and/or FMS-like tyrosine kinase (Fit) activity. The invention also relates in part to methods for using such molecules (I) wherein the substituents are defined as in the claims.

  该发明涉及部分具有式(I)的分子，具有某些生物活性，包括但不限于抑制细胞增殖、调节蛋白激酶活性和调节聚合酶活性。本发明的分子可以调节蛋白激酶CK2活性、Pim激酶活性和/或类FMS酪氨酸激酶（Fit）活性。本发明还涉及使用这些分子(I)的方法，其中取代基如权利要求所定义。
• NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
  申请人：HADDACH Mustapha

  公开号：US20110071136A1

  公开（公告）日：2011-03-24

  The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.

  这项发明提供了抑制CK2和/或Pim激酶的化合物以及含有这些化合物的组合物。这些三环化合物和含有它们的组合物对于治疗增殖性疾病如癌症以及其他与激酶相关的疾病条件包括炎症、疼痛、病原体感染和某些免疫性疾病是有用的。
• Androgen Receptor Modulators
  申请人：Wang Jiabing

  公开号：US20070269405A1

  公开（公告）日：2007-11-22

  Compounds of structural Formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

  结构式（I）的化合物以组织选择性的方式调节雄激素受体（AR），在增强肌肉张力和治疗由雄激素缺乏引起的或可以通过雄激素治疗改善的疾病中有用，包括骨质疏松症，骨质疏松症，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建手术后的骨损伤，肌肉萎缩，虚弱，老化皮肤，男性性腺功能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖症，再生障碍性贫血和其他造血系统疾病，炎性关节炎和关节修复，艾滋病浪费，前列腺癌，良性前列腺增生症（BPH），腹部脂肪堆积，代谢综合征，2型糖尿病，癌症恶病质，阿尔茨海默病，肌肉萎缩症，认知能力下降，性功能障碍，睡眠呼吸暂停，抑郁症，早发卵巢衰竭和自身免疫疾病，单独或与其他活性药物联合使用。
• NOVEL PROTEIN KINASE MODULATORS
  申请人：PIERRE Fabrice

  公开号：US20110065698A1

  公开（公告）日：2011-03-17

  The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate protein kinase CK2 activity, Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.

  本发明部分涉及具有某些生物活性的分子，包括但不限于抑制细胞增殖、调节蛋白激酶活性和调节聚合酶活性等。本发明的分子可以调节蛋白激酶CK2活性、Pim激酶活性和/或类FMS酪氨酸激酶(Flt)活性。本发明部分还涉及使用这些分子的方法。

表征谱图